Document is current
Any future updates will be listed below
-
Authors
Peng, Ziyi
Wang, Jingya
Guo, Jing
Li, Xin
Wang, Sheng
Xie, Ying
Jiang, Hongmei
Wang, Yixuan
Wang, Mengqi
Hu, Meilin
Li, Qian
Wang, Yafei
Mi, Jian-Qing
Liu, Zhiqiang https://orcid.org/0000-0002-0677-8097
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03502577 at ClinicalTrials.govDocuments that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
All-trans retinoic acid improves NSD2-mediated RARĪ± phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma
https://doi.org/10.1136/jitc-2022-006325
-
Funding
Funding for this research was provided by:
Shanghai Guangci Translational Medicine Research Foundation (N/A)
National Natural Science Foundation of China (81870161)
National Natural Science Foundation of China (81900215)
National Natural Science Foundation of China (82000216)
National Natural Science Foundation of China (82070221)
National Natural Science Foundation of China (82070227)
National Natural Science Foundation of China (82270208)
Beijing Natural Science Foundation of China (Z200020)
- License Information
